芦可替尼治疗难治性硬化性慢性移植物抗宿主病的多中心Ⅱ期试验
这项单臂多中心Ⅱ期试验纳入47例对糖皮质激素难治且至少接受过一线系统治疗的硬化性慢性移植物抗宿主病成人患者,接受芦可替尼至少6个月。6个月时皮肤和/或关节部分缓解率为49%(95% CI,34至64),总体cGVHD部分缓解率为47%(95% CI,32至61),12个月无失败生存率为77.1%(95% CI,61.3至87.0),非复发死亡率为2.2%(95% CI,0.17至10.3),无新安全信号。
要点
- 6个月时皮肤和/或关节部分缓解率为49%(95% CI,34至64),其中关节和筋膜缓解率45%,皮肤缓解率19%。
- 总体cGVHD部分缓解率为47%(95% CI,32至61),Lee症状量表总分及皮肤子量表改善者占38%。
- 12个月无失败生存率为77.1%(95% CI,61.3至87.0),非复发死亡率为2.2%(95% CI,0.17至10.3),无恶性肿瘤复发。
核心结论
- 芦可替尼在难治性硬化性cGVHD中与较高的皮肤/关节缓解率和总体cGVHD缓解率相关,患者报告结局改善,非复发死亡率低,无失败生存率高。
- 芦可替尼为难治性硬化性cGVHD提供了一种有效的治疗选择。
研究设计与样本
- 单臂多中心Ⅱ期试验,纳入47例对糖皮质激素难治且至少接受过一线系统治疗的硬化性cGVHD成人患者,接受芦可替尼至少6个月(ClinicalTrials.gov标识:NCT03616184)。
- 主要终点为根据2014年美国国立卫生研究院cGVHD共识标准定义的皮肤和/或关节完全或部分缓解。
主要发现
- 芦可替尼中位使用11个月后,6个月时皮肤和/或关节部分缓解率为49%(95% CI,34至64),其中关节和筋膜缓解率45%,皮肤缓解率19%。
- 皮肤/关节缓解持续时间在12个月时为77%(95% CI,48至91)。
- 总体cGVHD部分缓解率为47%(95% CI,32至61),Lee症状量表总分及皮肤子量表评分改善者占38%。
- 治疗失败累积发生率为20.8%(95% CI,10.0至34.1),非复发死亡率为2.2%(95% CI,0.17至10.3),无恶性肿瘤复发,12个月无失败生存率为77.1%(95% CI,61.3至87.0)。
- 芦可替尼总体耐受良好,无新安全信号。
关键数值与推荐
- 主要终点皮肤和/或关节部分缓解率:6个月时为49%(95% CI,34至64)。
- 关节和筋膜缓解率45%,皮肤缓解率19%。
- 皮肤/关节缓解持续时间:12个月时为77%(95% CI,48至91)。
- 总体cGVHD部分缓解率47%(95% CI,32至61)。
- 治疗失败累积发生率20.8%(95% CI,10.0至34.1),非复发死亡率2.2%(95% CI,0.17至10.3),12个月无失败生存率77.1%(95% CI,61.3至87.0)。
临床怎么用
- 原文结论认为芦可替尼为难治性硬化性cGVHD提供了一种有效的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with corticosteroid refractory sclerotic cGVHD. PATIENTS AND METHODS: In a single-arm multicenter phase II trial (N = 47), adults with sclerotic cGVHD refractory to corticosteroids and ≥one additional line of systemic therapy for cGVHD received ruxolitinib for ≥six months (ClinicalTrials.gov identifier: NCT03616184). The primary end point was complete or partial response (PR) in skin and/or joint defined according to the 2014 National Institute of Health cGVHD Consensus Criteria. RESULTS: Following the use of ruxolitinib for a median of 11 months, PR in skin and/or joints was noted in 49% (95% CI, 34 to 64) at 6 months, with 45% having joint and fascia response and 19% having skin response. The duration of skin/joint response was 77% (95% CI, 48 to 91) at 12 months. Overall cGVHD PR was noted in 47% (95% CI, 32 to 61). Improvement in Lee Symptom Scale summary and skin subscale scores was noted in 38% of patients. With a cumulative incidence of treatment failure of 20.8% (95% CI, 10.0 to 34.1), nonrelapse mortality (NRM) of 2.2% (95% CI, 0.17 to 10.3), and no recurrent malignancy, failure-free survival (FFS) was 77.1% (95% CI, 61.3 to 87.0) at 12 months. Ruxolitinib was overall well tolerated with no new safety signals. CONCLUSION: The use of ruxolitinib was associated with relatively high rates of skin/joint responses and overall cGVHD responses, improvement in patient-reported outcomes, low NRM, and high FFS in patients with refractory sclerotic cGVHD. Ruxolitinib offers an effective treatment option for refractory sclerotic cGVHD.
引用
- Bhatt VR, Shostrom VK, Choe HK, et al. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease. J Clin Oncol. 2024. PMID: 39151112. doi:10.1200/JCO.24.00205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。